Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 4/20 | 0.77 |
| ▸ | CAMK2D | Q13557 | 6/20 | 0.60 |
| ▸ | CDK4 | P11802 | 1/20 | 0.60 |
| ▸ | CCND3 | P30281 | 1/20 | 0.60 |
| ▸ | GSK3B | P49841 | 1/20 | 0.60 |
| ▸ | PRKCA | P17252 | 2/20 | 0.58 |
| ▸ | ABL1 | P00519 | 1/20 | 0.58 |
| ▸ | BCR | P11274 | 1/20 | 0.58 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.58 |
| ▸ | SYK | P43405 | 1/20 | 0.55 |
| ▸ | CDK2 | P24941 | 1/20 | 0.52 |
| ▸ | CLK1 | P49759 | 2/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.52 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.52 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.52 |
| ▸ | CLK2 | P49760 | 1/20 | 0.52 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.50 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.50 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.50 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30554620 | 0.89 | PLK1 (0.59) | PLK1CDK4CCND3GSK3BPRKCA | |
| SCHEMBL25339219 | 0.89 | PLK1 (0.59) | PLK1CDK4CCND3GSK3BPRKCA | |
| SCHEMBL2944816 | 0.89 | CLK1 (0.60) | PLK1GSK3BSYKCDK2CLK1 | |
| SCHEMBL4732841 | 0.87 | PLK1 (1.00) | PLK1CAMK2DCDK4CCND3GSK3B | |
| SCHEMBL25337631 | 0.85 | PLK1 (0.72) | PLK1CAMK2DABL1BCRSYK | |
| SCHEMBL30554478 | 0.85 | PLK1 (0.72) | PLK1CAMK2DABL1BCRSYK | |
| SCHEMBL2956376 | 0.85 | PLK1 (0.68) | PLK1CAMK2DCDK4CCND3GSK3B | |
| SCHEMBL14651462 | 0.84 | PLK1 (0.84) | PLK1CAMK2DCDK4GSK3BPRKCA | |
| SCHEMBL25339601 | 0.84 | PLK1 (0.54) | PLK1GSK3BPRKCAABL1BCR | |
| SCHEMBL30554555 | 0.84 | PLK1 (0.54) | PLK1GSK3BPRKCAABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210060158-A1 | AGONIST OF ARYL HYDROCARBON RECEPTOR FOR USE IN CANCER COMBINATION THERAPY | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2021-03-04 | — | — | US | claimed |
| EP-3684410-A1 | AGONIST OF ARYL HYDROCARBON RECEPTOR FOR USE IN CANCER COMBINATION THERAPY | Institut Curie (FR) | 2020-07-29 | — | — | EP | claimed |
| WO-2019057744-A1 | AGONIST OF ARYL HYDROCARBON RECEPTOR FOR USE IN CANCER COMBINATION THERAPY | INSTITUT CURIE (FR) | 2019-03-28 | — | — | WO | claimed |
| EP-3522902-B1 | PROBIOTIC BACTERIA PRODUCING AN AHR AGONIST AND THEIR USE IN THE TREATMENT OF METABOLIC SYNDROME AND OBESITY | INSTITUT NATIONAL DE RECH POUR LAGRICULTURE LALIMENTATION ET LENVIRONNEMENT (FR) | 2025-09-03 | — | — | EP | disclosed |
| US-20240208913-A1 | ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF | NEXYS THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240208913-A1 | ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF | NEXYS THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| WO-2023150197-A1 | ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF | NEXYS THERAPEUTICS, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| US-20230152314-A1 | LIPOCALIN-2 ASSAY FOR INTESTINAL ADAPTATION | THE JOHNS HOPKINS UNIVERSITY | 2023-05-18 | — | — | US | disclosed |
| US-20230095683-A1 | COPROCOCCUS BACTERIA FOR USE IN THE TREATMENT OF METABOLIC SYNDROME AND INFLAMMATORY BOWEL DISEASES | SORBONNE UNIVERSITE (FR) | 2023-03-30 | — | — | US | disclosed |
| US-11596657-B2 | Use of AhR agonist for the preventive or curative treatment of metabolic syndrome and the associated disorders | INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (FR) | 2023-03-07 | — | — | US | disclosed |
| EP-4114420-A1 | COPROCOCCUS BACTERIA FOR USE IN THE TREATMENT OF METABOLIC SYNDROME AND INFLAMMATORY BOWEL DISEASES | Institut national de recherche pour l'agriculture, l'alimentation et l'environnement (FR) | 2023-01-11 | — | — | EP | disclosed |
| US-20080279829-A1 | Phenyl-(4-Phenyl-Pyrimidin-2-Yl)-Amines For Enhancing Immunotolerance | WOISETSCHLAEGER MAXIMILIAN | 2008-11-13 | — | — | US | disclosed |
| EP-1474146-B1 | PHENYLPYRIMIDINE AMINES AS IGE INHIBITORS | NOVARTIS AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| EP-1933839-A1 | PHENYL-(4-PHENYL-PYRIMIDIN-2-YL)-AMINES FOR ENHANCING IMMUNOTOLERANCE | Novartis AG (CH) | 2008-06-25 | — | — | EP | disclosed |
| US-20070281956-A1 | Phenylpyrimidine amines as IgE inhibitors | NOVARTIS AG (CH) | 2007-12-06 | — | — | US | disclosed |
| WO-2007039216-A1 | PHENYL-(4-PHENYL-PYRIMIDIN-2-YL)-AMINES FOR ENHANCING IMMUNOTOLERANCE | NOVARTIS AG (CH) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039216-A1 | PHENYL-(4-PHENYL-PYRIMIDIN-2-YL)-AMINES FOR ENHANCING IMMUNOTOLERANCE | NOVARTIS AG (CH) | 2007-04-12 | — | — | WO | disclosed |
| US-20050119255-A1 | Phenylpyrimidine amines as ige inhibitors | BULUSU MURTY (AT) | 2005-06-02 | — | — | US | disclosed |
| EP-1474146-A1 | PHENYLPYRIMIDINE AMINES AS IGE INHIBITORS | Novartis AG (CH) | 2004-11-10 | — | — | EP | disclosed |
| WO-2003063871-A1 | PHENYLPYRIMIDINE AMINES AS IGE INHIBITORS | NOVARTIS AG (CH) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080279829-A1 | Phenyl-(4-Phenyl-Pyrimidin-2-Yl)-Amines For Enhancing Immunotolerance | IFNG, IL2, LY96 | PLK1 1369/4885CAMK2D 3622/4885CDK4 2063/4885 |
| US-20240208913-A1 | ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF | AHR, ARNT, NR1H2 | PLK1 4810/4885CAMK2D 1708/4885CDK4 3495/4885 |
| US-20070281956-A1 | Phenylpyrimidine amines as IgE inhibitors | FCER2, SELP, FCGR2A | PLK1 1234/4885CAMK2D 1891/4885CDK4 692/4885 |
| US-20050119255-A1 | Phenylpyrimidine amines as ige inhibitors | FCER2, SELP, FCGR2A | PLK1 1234/4885CAMK2D 1891/4885CDK4 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.